Adams Tackles Branding By Linking Mucinex To Mucus, Not Indications
This article was originally published in The Tan Sheet
Executive SummaryAdams Respiratory Therapeutics competes head on with larger firms in the over-the-counter market, but on its own terms using untraditional approaches to building brand recognition, Adams President and CEO Michael Valentino says
You may also be interested in...
Consumer health product firms say the coronavirus will have an impact on their results, but it’s too early to estimate the costs. US FDA also hedges its predictions, saying the outbreak could lead to interruptions in country’s drug and medical device supplies. China's health commission has issued six guidelines for diagnosis and treatment, but no conventional antiviral treatment is approved and it's emphasizing traditional Chinese medicines.